
  
    
      
        Background_NNP
        RU_NNP 486_CD (_( Mifepristone_NNP )_) has_VBZ shown_VBN remarkable_JJ
        antiglucocorticoid_NN and_CC antiprogestrone_NN activities_NNS both_DT 
        in_IN vitro_NN and_CC 
        in_IN vivo_NN [_NN 1_CD 2_CD ]_NN ._. This_DT compound_NN has_VBZ a_DT
        high_JJ affinity_NN for_IN ligand_NN binding_JJ sites_NNS of_IN both_DT receptors_NNS [_NN
        1_CD 2_CD ]_NN ._. Current_JJ clinical_JJ uses_NNS of_IN RU_NNP 486_CD are_VBP limited_VBN to_TO its_PRP$
        function_NN as_IN a_DT progestrone_NN antagonist_NN [_NN 1_CD 2_CD ]_NN ,_, where_WRB it_PRP was_VBD
        approved_VBN in_IN France_NNP in_IN 1988_CD ,_, and_CC recently_RB in_IN the_DT USA_NNP as_IN a_DT
        means_NN to_TO induce_VB early_JJ termination_NN of_IN pregnancy_NN [_NN 1_CD 2_CD 3_CD ]_NN
        ._.
        Based_VBN on_IN its_PRP$ antiprogesterone_NN activity_NN ,_, RU_NNP 486_CD has_VBZ been_VBN
        evaluated_VBN as_IN a_DT useful_JJ anticancer_NN agent_NN in_IN organs_NNS sensitive_JJ
        to_TO this_DT hormone_NN [_NN 4_CD ]_NN ._. Although_IN evidence_NN was_VBD not_RB
        conclusive_JJ in_IN these_DT studies_NNS ,_, RU_NNP 486_CD demonstrated_VBD a_DT benefit_NN
        to_TO humans_NNS suffering_VBG from_IN meningioma_NN ,_, breast_NN cancer_NN and_CC
        uterine_NN leiomyomata_NN [_NN 4_CD ]_NN ._. Several_JJ 
        in_IN vitro_NN studies_NNS also_RB demonstrated_VBN
        that_IN RU_NNP 486_CD induced_VBN antiproliferative_JJ effects_NNS against_IN murine_NN
        mammary_JJ tumors_NNS [_NN 5_CD ]_NN as_RB well_RB as_IN cultured_JJ human_JJ endometrial_NN
        stromal_NN and_CC epithelial_NN cells_NNS [_NN 6_CD 7_CD ]_NN ._.
        Antagonizing_NNP the_DT effects_NNS of_IN glucocorticoids_NNS by_IN RU_NNP 486_CD
        may_MD ,_, however_RB ,_, result_NN in_IN deleterious_JJ effects_NNS ._.
        Glucocorticoids_NNP produce_VB a_DT receptor-mediated_JJ inhibitory_NN
        effect_NN on_IN both_DT basal_NN and_CC hormone-stimulated_JJ expression_NN of_IN a_DT
        newly_RB discovered_VBN family_NN of_IN molecules_NNS known_VBN as_IN suppressors_NNS
        of_IN cytokine_NN signalling_VBG [_NN 8_CD ]_NN ._. These_DT molecules_NNS play_VBP an_DT
        important_JJ role_NN in_IN shutting_VBG off_IN cytokine_NN action_NN [_NN 8_CD ]_NN ,_, and_CC
        RU_NNP 486_CD may_MD therefore_RB augment_VB cytokine-mediated_JJ effects_NNS ._.
        Indeed_RB ,_, since_IN tumor_NN necrosis_NNS factor_NN 
        alpha_NN (_( TNFα_NNP )_) is_VBZ known_VBN to_TO suppress_VB
        hepatic_JJ apoptosis_NNS [_NN 9_CD ]_NN ,_, a_DT function_NN which_WDT is_VBZ considered_VBN a_DT
        safeguard_VB mechanism_NN against_IN neoplasia_NN [_NN 10_CD 11_CD ]_NN ,_, the_DT
        reported_VBN ability_NN of_IN RU_NNP 486_CD to_TO elevate_NN hepatic_JJ TNFα_NNP
        production_NN 
        in_IN vivo_NN and_CC to_TO enhance_VB cell_NN
        sensitivity_NN to_TO its_PRP$ toxic_JJ effects_NNS is_VBZ alarming_JJ [_NN 12_CD ]_NN ._.
        Glucocorticoids_NNP also_RB inhibit_VBP hepatocellular_NN proliferation_NN [_NN
        13_CD 14_CD 15_CD ]_NN and_CC modulate_VBP the_DT expression_NN of_IN oncogenes_NNS and_CC
        tumor_NN suppressor_NN genes_NNS [_NN 11_CD ]_NN ,_, 
        via_IN mechanisms_NNS involving_VBG the_DT
        glucocorticoid_NN receptor_NN [_NN 16_CD 17_CD 18_CD ]_NN ,_, further_JJ supporting_VBG
        the_DT notion_NN that_IN inhibiting_VBG these_DT receptors_NNS may_MD result_VB in_IN
        harmful_JJ effects_NNS ._.
        We_PRP tested_VBD the_DT hypothesis_NNS that_WDT inhibition_NN of_IN the_DT
        glucocorticoid_NN receptor_NN will_MD trigger_VB events_NNS that_WDT may_MD
        ultimately_RB lead_VB to_TO liver_NN cancer_NN ._. Consequently_RB ,_, we_PRP
        investigated_VBD the_DT impact_NN of_IN RU_NNP 486_CD on_IN hepatocellular_NN
        proliferation_NN and_CC programmed_VBN cell_NN death_NN in_IN livers_NNS of_IN male_JJ
        B_NNP 6_CD C_NNP 3_CD F_NN 1_CD mice_NNS ,_, and_CC quantified_VBN hepatic_JJ levels_NNS of_IN genes_NNS
        involved_VBN in_IN these_DT events_NNS ._.
      
      
        Results_NNS
        
          Effect_NN of_IN RU_NNP 486_CD on_IN hepatocellular_NN proliferation_NN
          and_CC apoptosis_NNS
          In_IN control_NN mice_NNS ,_, 1_CD ._. 55_CD ±_NN 0_CD ._. 12_CD %_NN of_IN hepatocytes_NNS were_VBD
          labeled_VBN with_IN BrDU_NNP (_( Fig_NNP ._. 1_LS A_DT )_) ._. Treatment_NNP with_IN RU_NNP 486_CD
          significantly_RB diminished_VBD these_DT labeling_VBG indices_NNS by_IN
          approximately_RB 45_CD %_NN to_TO 0_CD ._. 86_CD ±_NN 0_CD ._. 039_CD %_NN (_( Fig_NNP 1_CD A_DT )_) ._. Similarly_RB ,_,
          RU_NNP 486_CD caused_VBD a_DT remarkable_JJ decrease_NN in_IN programmed_VBN cell_NN
          death_NN in_IN the_DT liver_NN ._. In_IN control_NN animals_NNS ,_, 2_CD ._. 68_CD ±_NN 0_CD ._. 7_CD %_NN of_IN
          hepatocytes_NNS were_VBD undergoing_VBG apoptosis_NNS (_( Fig_NNP 1_CD B_NNP )_) ._. These_DT
          levels_NNS were_VBD significantly_RB reduced_VBN by_IN 66_CD %_NN to_TO 0_CD ._. 9_CD ±_NN 0_CD ._. 16_CD %_NN
          in_IN livers_NNS of_IN mice_NNS pretreated_JJ with_IN RU_NNP 486_CD (_( Fig_NNP 1_CD B_NNP )_) ._.
        
        
          Increasing_VBG oncogene_NN mRNA_NN expression_NN by_IN RU_NNP
          486_CD
          Pretreatment_NNP of_IN mice_NNS with_IN RU_NNP 486_CD caused_VBN significant_JJ
          increases_NNS in_IN hepatic_JJ levels_NNS of_IN JunB_NNP and_CC mdm_NN 2_CD (_( Fig_NNP 2_LS )_) ._. A_DT
          remarkable_JJ 2_CD ._. 5_CD -_: fold_VB increase_NN in_IN the_DT mRNA_NN of_IN JunB_NNP was_VBD
          detected_VBN upon_IN treatment_NN with_IN RU_NNP 486_CD (_( Fig_NNP 2_CD A_DT )_) ._. RU_NNP 486_CD also_RB
          increased_VBD the_DT hepatic_JJ mRNA_NN levels_NNS of_IN the_DT oncogene_NN mdm_NN 2_CD by_IN
          21_CD ±_NN 7_CD %_NN (_( Fig_NNP 2_CD B_NNP )_) ._.
        
        
          Decreasing_NNP Liver_NNP mRNA_NN Levels_NNP of_IN c-myc_JJ and_CC p_NN 53_CD by_IN
          RU_NNP 486_CD
          In_IN contrast_NN to_TO its_PRP$ effect_NN on_IN JunB_NNP and_CC mdm_NN 2_CD mRNA_NN
          levels_NNS ,_, RU_NNP 486_CD diminished_VBD the_DT hepatic_JJ expression_NN of_IN c-myc_JJ
          and_CC p_NN 53_CD mRNAs_NNS to_TO comparable_JJ degrees_NNS (_( Fig_NNP 3_LS )_) ._. While_IN mRNA_NN
          of_IN c-myc_JJ was_VBD significantly_RB decreased_VBN by_IN approximately_RB 25_CD
          ±_NN 3_CD %_NN (_( Fig_NNP 3_CD A_DT )_) ,_, that_IN of_IN p_NN 53_CD was_VBD also_RB diminished_VBN
          significantly_RB by_IN about_IN 21_CD ±_NN 5_CD %_NN in_IN the_DT livers_NNS of_IN animals_NNS
          treated_VBN with_IN RU_NNP 486_CD ,_, compared_VBN to_TO control_VB mice_NNS (_( Fig_NNP
          3_CD B_NNP )_) ._.
        
      
      
        Discussion_NNP
        
          Effect_NN of_IN RU_NNP 486_CD on_IN liver_NN cell_NN proliferation_NN
          Glucocorticoids_NNP have_VBP been_VBN shown_VBN in_IN various_JJ studies_NNS to_TO
          inhibit_VB DNA_NNP synthesis_NN [_NN 13_CD 14_CD 15_CD ]_NN ._. Therefore_RB ,_, we_PRP
          hypothesized_VBN that_IN blocking_VBG the_DT glucocorticoid_NN receptor_NN by_IN
          the_DT potent_JJ antagonist_NN RU_NNP 486_CD would_MD result_VB in_IN increased_VBN
          incorporation_NN of_IN BrDU_NNP into_IN hepatocyte_NN DNA_NNP ,_, indicating_VBG an_DT
          enhanced_VBN cellular_JJ proliferative_JJ capability_NN ._. Indeed_RB ,_, RU_NNP 486_CD
          caused_VBD a_DT remarkable_JJ 2_CD ._. 5_CD -_: fold_VB increase_NN in_IN the_DT expression_NN
          of_IN junB_NN mRNA_NN (_( Fig_NNP 2_CD A_DT )_) ._. The_DT protein_NN product_NN of_IN this_DT gene_NN
          is_VBZ a_DT member_NN of_IN the_DT activating_VBG protein-_NN 1_CD (_( AP-_NNP 1_LS )_) family_NN [_NN
          19_CD ]_NN ,_, which_WDT upon_IN binding_JJ to_TO either_CC c-fos_JJ or_CC fos_NNS B_NNP
          protein_NN form_NN a_DT complex_NN that_WDT have_VBP high_JJ affinity_NN to_TO AP-_NNP 1_CD
          binding_JJ concensus_JJ sequence_NN [_NN 20_CD ]_NN ._. A_DT wide_JJ variety_NN of_IN
          chemicals_NNS ,_, including_VBG growth_NN factors_NNS ,_, and_CC tumor_NN promotors_NNS
          increase_VBP the_DT expression_NN of_IN this_DT gene_NN in_IN various_JJ cell_NN
          types_NNS [_NN 21_CD ]_NN ._. Compared_VBN to_TO untransfected_JJ keratinocytes_NNS ,_,
          JunB-transfected_NNP cells_NNS grew_VBD more_RBR rapidly_RB ,_, and_CC were_VBD highly_RB
          invasive_JJ in_IN an_DT 
          in_IN vitro_NN assay_NN [_NN 22_CD ]_NN ._. Therefore_RB ,_,
          the_DT increased_VBN hepatic_JJ levels_NNS of_IN junB_NN gene_NN ,_, in_IN mice_NNS
          treated_VBN with_IN RU_NNP 486_CD ,_, was_VBD expected_VBN to_TO reflect_VB an_DT
          uncontrolled_JJ hepatocellular_NN growth_NN in_IN these_DT animals_NNS ._.
          Surprisingly_RB ,_, however_RB ,_, RU_NNP 486_CD diminished_VBD the_DT capacity_NN of_IN
          liver_NN cells_NNS to_TO proliferate_VBP (_( Fig_NNP 1_CD A_DT )_) ._. In_IN order_NN to_TO explain_VB
          this_DT discrepancy_NN ,_, it_PRP is_VBZ noteworthy_JJ to_TO mention_VB that_IN
          unrelated_JJ to_TO its_PRP$ anti-glucocorticoid_JJ activity_NN ,_, RU_NNP 486_CD also_RB
          has_VBZ antioxidant_NN properties_NNS that_WDT have_VBP been_VBN suggested_VBN to_TO
          play_VB a_DT role_NN in_IN the_DT inhibition_NN of_IN cell_NN growth_NN caused_VBN by_IN
          this_DT compound_NN [_NN 7_CD ]_NN ._. Such_JJ an_DT effect_NN and_CC /_NN or_CC other_JJ
          anti-glucocorticoid-independent_JJ influences_NNS by_IN RU_NNP 486_CD
          appears_VBZ to_TO prevail_VB in_IN relation_NN to_TO the_DT overall_JJ impact_NN of_IN
          this_DT compound_NN on_IN cell_NN proliferation_NN ,_, and_CC may_MD indeed_RB
          suggest_VB ,_, at_IN a_DT first_JJ glance_NN ,_, a_DT protective_JJ effect_NN against_IN
          the_DT risk_NN of_IN hepatocellular_NN cancer_NN ._.
        
        
          Diminishing_NNP liver_NN capacity_NN to_TO eliminate_VB
          pre-cancerous_JJ hepatocytes_NNS
          Despite_IN the_DT decrease_NN in_IN hepatocellular_NN proliferation_NN
          caused_VBN by_IN RU_NNP 486_CD ,_, inhibition_NN of_IN hepatic_JJ apoptosis_NNS in_IN
          animals_NNS treated_VBN with_IN this_DT compound_NN (_( Fig_NNP 1_CD B_NNP )_) represents_VBZ a_DT
          potentially_RB deleterious_JJ effect_NN ._. Apoptosis_NNP is_VBZ considered_VBN a_DT
          safeguard_VB that_WDT enables_VBZ an_DT organ_NN to_TO purge_VB itself_PRP of_IN
          transformed_VBN cells_NNS [_NN 10_CD 11_CD ]_NN ,_, and_CC its_PRP$ inhibition_NN is_VBZ
          proposed_VBN as_IN a_DT mechanism_NN by_IN which_WDT non-genotoxic_JJ
          hepatocarcinogens_NNS produce_VBP liver_NN cancer_NN [_NN 9_CD 23_CD ]_NN ._. We_PRP
          examined_VBD the_DT effect_NN of_IN RU_NNP 486_CD on_IN the_DT hepatic_JJ expression_NN
          of_IN two_CD genes_NNS involved_VBN in_IN the_DT regulation_NN of_IN this_DT function_NN
          [_NN 10_CD 11_CD ]_NN ,_, c-myc_JJ and_CC p_NN 53_CD ,_, to_TO evaluate_VB how_WRB RU_NNP 486_CD might_MD
          inhibit_VB apoptosis_NNS ._. This_DT compound_NN diminished_VBD the_DT hepatic_JJ
          mRNA_NN expression_NN of_IN both_DT c-myc_JJ and_CC p_NN 53_CD significantly_RB (_( Fig_NNP
          3_LS )_) ._. We_PRP previously_RB reported_VBD that_WDT enhanced_JJ liver_NN apoptosis_NNS
          in_IN response_NN to_TO the_DT antihepatocarcinogen_NN rotenone_NN was_VBD
          preceded_VBN and_CC accompanied_VBN by_IN a_DT marked_VBN increase_NN in_IN the_DT
          hepatic_JJ levels_NNS of_IN c-myc_JJ mRNA_NN [_NN 10_CD ]_NN ,_, a_DT proto-oncogene_JJ
          that_WDT plays_VBZ a_DT dual_JJ role_NN in_IN cell_NN proliferation_NN and_CC
          apoptosis_NNS [_NN 24_CD ]_NN ._. Since_IN in_IN our_PRP$ study_NN [_NN 10_CD ]_NN rotenone_NN
          inhibited_VBD hepatocellular_NN proliferation_NN while_IN enhancing_VBG
          apoptosis_NNS ,_, we_PRP concluded_VBD that_IN the_DT increase_NN in_IN c-myc_JJ mRNA_NN
          expression_NN acted_VBD as_IN a_DT pro-apoptotic_JJ signal_NN in_IN the_DT liver_NN ._.
          Also_RB ,_, p_NN 53_CD modulates_NNS a_DT battery_NN of_IN downstream_JJ genes_NNS
          involved_VBN in_IN growth_NN control_NN and_CC apoptosis_NNS [_NN 25_CD 26_CD ]_NN ._.
          Taken_VBN collectively_RB ,_, diminishing_VBG liver_NN mRNA_NN levels_NNS of_IN both_DT
          c-myc_JJ and_CC p_NN 53_CD by_IN RU_NNP 486_CD may_MD help_VB define_VB the_DT underlying_VBG
          reasons_NNS for_IN the_DT observed_VBN anti-apoptotic_JJ activity_NN of_IN this_DT
          compound_NN ._.
          In_IN addition_NN to_TO its_PRP$ effects_NNS on_IN mRNA_NN of_IN c-myc_JJ and_CC p_NN 53_CD ,_,
          RU_NNP 486_CD significantly_RB increased_VBN that_IN of_IN the_DT oncogene_NN mdm_NN 2_CD
          by_IN approximately_RB 20_CD %_NN (_( Fig_NNP 2_CD B_NNP )_) ._. The_DT protein_NN product_NN of_IN the_DT
          mdm_NN 2_CD oncogene_NN is_VBZ over-expressed_JJ in_IN a_DT considerable_JJ number_NN
          of_IN tumors_NNS [_NN 27_CD ]_NN ._. This_DT protein_NN is_VBZ a_DT pivotal_JJ negative_JJ
          regulator_NN of_IN p_NN 53_CD [_NN 27_CD ]_NN ;_: it_PRP interacts_NNS with_IN the_DT P_NN 53_CD
          protein_NN masking_VBG its_PRP$ transcriptional_NN domain_NN and_CC
          accelerating_VBG its_PRP$ proteasomal_NN degradation_NN [_NN 21_CD 27_CD ]_NN ._. The_DT
          later_JJ process_NN involves_VBZ the_DT deacetylation_NN and_CC
          ubiquitylation_NN of_IN the_DT p_NN 53_CD protein_NN by_IN mdm_NN 2_CD [_NN 28_CD ]_NN ._.
          Inactivation_NNP and_CC /_NN or_CC degradation_NN of_IN p_NN 53_CD diminishes_VBZ the_DT
          cell_NN ability_NN to_TO undergo_VB apoptosis_NNS [_NN 21_CD ]_NN ._. Conversely_RB ,_,
          p_NN 53_CD may_MD influence_VB mdm_NN 2_CD ._. Over-expression_NNP of_IN
          homeodomain-interacting_JJ protein_NN kinase_NN 2_CD (_( HIPK_NNP 2_LS )_) ,_, which_WDT
          increases_VBZ p_NN 53_CD protein_NN expression_NN and_CC /_NN or_CC stability_NN ,_, leads_VBZ
          to_TO a_DT downregulation_NN of_IN mdm_NN 2_CD protein_NN ,_, but_CC not_RB mRNA_NN [_NN 29_CD ]_NN
          ._. Consequently_RB ,_, the_DT RU_NNP 486_CD -_: induced_VBN increase_NN in_IN mdm_NN 2_CD mRNA_NN
          expression_NN ,_, coupled_VBN with_IN a_DT decrease_NN in_IN that_DT of_IN P_NN 53_CD ,_, may_MD
          also_RB act_VB in_IN tandem_JJ to_TO suppress_VB the_DT liver_NN apoptotic_JJ
          capacity_NN (_( Fig_NNP 1_CD B_NNP )_) ._.
        
        
          NF-κB_NNP and_CC the_DT glucocorticoid_NN receptor_NN
          The_DT transcription_NN factor_NN NF-κB_NNP plays_VBZ a_DT critical_JJ role_NN
          in_IN controlling_VBG expression_NN of_IN downstream_JJ target_NN genes_NNS in_IN
          immune_JJ and_CC inflammatory_JJ responses_NNS ,_, development_NN ,_, and_CC
          apoptosis_NNS [_NN 30_CD ]_NN ._. Important_NNP advances_NNS have_VBP been_VBN made_VBN in_IN
          understanding_VBG the_DT signal_NN transduction_NN cascades_NNS that_WDT
          control_NN NF-κB_NNP activation_NN ._. Several_JJ lines_NNS of_IN evidence_NN
          indicate_VBP that_IN NF-κB_NNP is_VBZ constitutively_RB activated_VBN in_IN cancer_NN
          cells_NNS ,_, suggesting_VBG that_IN it_PRP plays_VBZ an_DT important_JJ role_NN in_IN
          tumorigenesis_NNS [_NN 30_CD ]_NN ._. Activated_NNP glucocorticoid_NN receptors_NNS
          have_VBP been_VBN shown_VBN to_TO repress_NNS NF-κB-mediated_NNP gene_NN expression_NN
          [_NN 31_CD ]_NN ,_, and_CC to_TO cause_VB a_DT significant_JJ reduction_NN in_IN nuclear_JJ
          levels_NNS of_IN p_NN 65_CD protein_NN ,_, a_DT subunit_NN of_IN NF-κB_NNP [_NN 31_CD ]_NN ._. A_DT
          variety_NN of_IN mitogens_NNS ,_, cytokines_NNS ,_, and_CC reactive_JJ oxygen_NN
          intermediates_NNS have_VBP been_VBN shown_VBN to_TO rapidly_RB cause_VB the_DT
          translocation_NN of_IN NF-κB_NNP to_TO the_DT nucleus_NN [_NN 30_CD 31_CD 32_CD ]_NN ,_, and_CC
          the_DT ability_NN of_IN dexamethasone_NN to_TO interfere_VB with_IN this_DT
          translocation_NN is_VBZ blocked_VBN by_IN prior_JJ treatment_NN with_IN the_DT
          glucocorticoid_NN antagonist_NN RU_NNP 486_CD [_NN 30_CD ]_NN ._. Based_VBN on_IN these_DT
          findings_NNS ,_, it_PRP is_VBZ plausible_JJ to_TO speculate_VB that_DT exposure_NN to_TO
          RU_NNP 486_CD may_MD interfere_VB with_IN the_DT function_NN of_IN endogenous_JJ
          glucocorticoids_NNS as_IN regulators_NNS of_IN cell_NN cycle_NN ,_, allowing_VBG the_DT
          initiation_NN and_CC progression_NN of_IN malignant_JJ transformation_NN of_IN
          liver_NN cells_NNS ._.
          Other_JJ mechanisms_NNS that_WDT may_MD participate_VB in_IN the_DT RU_NNP
          486_CD -_: induced_VBN inhibition_NN of_IN hepatic_JJ apoptosis_NNS include_VBP the_DT
          fact_NN that_IN this_DT compound_NN blocks_VBZ the_DT inhibitory_NN effect_NN of_IN
          glucocorticoids_NNS on_IN suppressors_NNS of_IN cytokine_NN signalling_VBG in_IN
          the_DT liver_NN [_NN 8_CD ]_NN ._. This_DT family_NN of_IN proteins_NNS is_VBZ induced_VBN by_IN
          growth_NN hormones_NNS and_CC cytokines_NNS ,_, and_CC is_VBZ strongly_RB repressed_JJ 
          in_IN vivo_NN by_IN glucocorticoids_NNS [_NN 8_CD ]_NN ._.
          Up-regulation_NNP of_IN these_DT proteins_NNS by_IN RU_NNP 486_CD [_NN 8_CD ]_NN ,_, coupled_VBN
          with_IN significant_JJ increase_NN in_IN hepatic_JJ TNFα_NNP level_NN found_VBD in_IN
          animals_NNS treated_VBN with_IN RU_NNP 486_CD [_NN 12_CD ]_NN ,_, may_MD contribute_VB to_TO
          the_DT inhibition_NN of_IN apoptosis_NNS observed_VBD in_IN our_PRP$ study_NN (_( Fig_NNP
          1_CD B_NNP )_) ._. Increased_VBN liver_NN production_NN of_IN TNFα_NNP has_VBZ been_VBN promoted_VBN
          as_IN a_DT significant_JJ factor_NN in_IN the_DT mechanism_NN by_IN which_WDT
          non-genotoxic_JJ hepatocarcinogens_NNS produce_VBP their_PRP$ effect_NN [_NN 9_CD
          ]_NN ._.
        
      
      
        Conclusion_NNP
        RU_NNP 486_CD has_VBZ recently_RB become_VBN available_JJ in_IN the_DT USA_NNP for_IN
        clinical_JJ use_NN as_IN an_DT effective_JJ non-surgical_JJ means_VBZ to_TO induce_VB
        abortion_NN ._. The_DT inhibitory_NN effect_NN of_IN this_DT compound_NN on_IN
        hepatocellular_NN apoptosis_NNS ,_, observed_VBD in_IN this_DT study_NN ,_, raises_VBZ
        questions_NNS about_IN the_DT potentially_RB deleterious_JJ impact_NN of_IN RU_NNP
        486_CD ._. A_DT single_JJ dose_NN of_IN RU_NNP 486_CD such_JJ as_IN that_DT recommended_VBD for_IN
        abortion_NN ,_, or_CC possible_JJ long-term_JJ treatment_NN with_IN this_DT drug_NN in_IN
        the_DT future_NN for_IN other_JJ therapeutic_JJ purposes_NNS could_MD potentially_RB
        initiate_VB events_NNS that_WDT could_MD increase_VB the_DT risk_NN of_IN hepatic_JJ
        cancer_NN ._. Such_JJ an_DT effect_NN would_MD be_VB of_IN special_JJ concern_NN for_IN
        individuals_NNS concurrently_RB exposed_VBN to_TO other_JJ carcinogens_NNS ._.
      
      
        Methods_NNP
        
          Chemicals_NNS and_CC supplies_NNS
          TRI_NNP REAGENT_NNP was_VBD the_DT product_NN of_IN Sigma_NNP Chemical_NNP Co_NNP ,_, St_NNP
          Louis_NNP ,_, MO_NNP ,_, while_IN MAXI_NNP script_NN ™_NN labeling_VBG kit_NN and_CC the_DT
          Ribonuclease_NNP Protection_NNP Assay_NNP kit_NN were_VBD purchased_VBN from_IN
          Ambion_NNP ,_, Inc_NNP ,_, Austin_NNP ,_, TX_NNP ._. 32_CD P_NN UTP_NNP was_VBD obtained_VBN from_IN NEN_NNP
          Life_NNP Science_NNP Products_NNPS ,_, Inc_NNP ,_, Boston_NNP ,_, MA_NNP ._. ApopTag_NNP ™_NN kit_NN was_VBD
          purchased_VBN from_IN Intergen_NNP (_( Purchase_NNP ,_, NY_NNP )_) ._. Probes_NNP for_IN mdm_NN 2_CD ,_,
          JunB_NNP ,_, c-myc_JJ and_CC β-actin_JJ genes_NNS were_VBD also_RB obtained_VBN from_IN
          Ambion_NNP ,_, lnc_NN ._. (_( Austin_NNP ,_, TX_NNP )_) ._.
        
        
          Animal_NNP treatment_NN
          Male_NNP B_NNP 6_CD C_NNP 3_CD F_NN 1_CD mice_NNS (_( Charles_NNP River_NNP ,_, Portage_NNP ._. Michigan_NNP )_)
          weighing_VBG 20_CD -_: 25_CD g_SYM were_VBD maintained_VBN on_IN a_DT daily_JJ cycle_NN of_IN
          alternating_VBG 12_CD hours_NNS periods_NNS of_IN light_JJ and_CC darkness_NNS ._. Mice_NNS
          received_VBD the_DT glucocorticoid_NN antagonist_NN RU_NNP 486_CD (_( 2_CD mg_NN /_NN k_NN /_NN day_NN ,_,
          ip_NN )_) ,_, or_CC a_DT corn_NN oil_NN vehicle_NN for_IN 7_CD days_NNS ._. Care_NNP and_CC handling_NN
          of_IN animals_NNS were_VBD in_IN accordance_NN with_IN the_DT guidelines_NNS of_IN the_DT
          USDA_NNP through_IN the_DT Animal_NNP Welfare_NNP Act_NNP Guide_NNP for_IN the_DT Care_NNP
          and_CC Use_NN of_IN Laboratory_NNP Animals_NNPS ,_, Department_NNP of_IN Health_NNP and_CC
          Human_NNP Services_NNPS Publication_NNP No_DT 85_CD -_: 23_CD ._.
        
        
          Ribonuclease_NNP protection_NN assay_NN (_( RPA_NNP )_)
          Hepatic_NNP RNA_NNP was_VBD extracted_VBN and_CC quantified_VBN as_IN we_PRP
          reported_VBD previously_RB [_NN 10_CD ]_NN ._. RNA_NNP was_VBD mixed_VBN with_IN
          32_CD P-_NNP labeled_VBD c-myc_JJ ,_, mdm_NN 2_CD ,_, p_NN 53_CD ,_, JunB_NNP ,_, and_CC β-actin_JJ probes_NNS ,_,
          then_RB co-precipitated_JJ ,_, purified_JJ ,_, and_CC electrophoresed_JJ on_IN 5_CD %_NN
          polyacrylamide_NN gel_NN ._. Following_VBG electrophoresis_NNS ,_, gels_NNS were_VBD
          exposed_VBN to_TO X-_NNP ray_NN film_NN overnight_JJ ._. Band_NNP intensities_NNS were_VBD
          quantified_VBN using_VBG Molecular_NNP Analyst_NNP software_NN and_CC a_DT GS-_NNP 250_CD
          Molecular_NNP Imager_NNP (_( Bio-_NNP Rad_NNP Laboratories_NNPS ,_, Hercules_NNP CA_NNP )_) ._.
        
        
          Hepatocellular_NNP proliferation_NN and_CC apoptosis_NNS
          Bromodeoxyuridine_NNP (_( BrDU_NNP )_) incorporation_NN into_IN DNA_NNP ,_, a_DT
          measure_NN of_IN cell_NN proliferation_NN ,_, and_CC enzymatic_JJ end_NN labeling_VBG
          of_IN 3_CD '_POS -_: hydroxy-_NN DNA_NNP strand_NN breaks_NNS ,_, a_DT measure_NN of_IN apoptosis_NNS ,_,
          were_VBD quantified_VBN 
          in_IN situ_NN as_IN we_PRP have_VBP reported_VBN
          previously_RB [_NN 10_CD ]_NN ._.
        
        
          Statistical_NNP analysis_NN
          Means_NNS of_IN the_DT two_CD experimental_JJ groups_NNS were_VBD compared_VBN
          using_VBG the_DT Student_NNP t-test_JJ ._. Statistical_NNP significance_NN was_VBD
          defined_VBN as_IN p_NN <_NN 0_CD ._. 05_CD ._. All_DT data_NNS reported_VBD are_VBP means_VBZ ±_NN SEM_NNP
          of_IN 3_CD -_: 6_CD mice_NNS per_IN group_NN ._.
        
      
      
        Authors_NNP '_'' contributions_NNS
        JY_NNP performed_VBD the_DT cell_NN proliferation_NN and_CC apoptosis_NNS
        assays_NNS ,_, and_CC carried_VBD out_IN related_VBN analyses_NNS ._. MB_NNP conceived_VBD ,_,
        designed_VBN and_CC coordinated_VBN the_DT study_NN ._. Both_DT authors_NNS
        participated_VBD in_IN writing_VBG the_DT manuscript_NN ._.
      
    
  
